Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $43.80 Consensus Price Target from Analysts

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) have received a consensus rating of "Moderate Buy" from the five analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $43.80.

Several brokerages recently commented on COLL. Needham & Company LLC reiterated a "buy" rating and issued a $46.00 target price on shares of Collegium Pharmaceutical in a report on Wednesday, April 9th. Wall Street Zen lowered Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, April 19th. HC Wainwright reissued a "buy" rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. Finally, Piper Sandler reissued a "neutral" rating and issued a $37.00 price target (up from $36.00) on shares of Collegium Pharmaceutical in a research note on Friday, May 9th.

Collegium Pharmaceutical Trading Up 0.1%

COLL stock traded up $0.04 during trading on Friday, hitting $28.86. The company had a trading volume of 178,265 shares, compared to its average volume of 427,547. The business has a 50-day moving average of $28.11 and a 200-day moving average of $29.74. Collegium Pharmaceutical has a one year low of $23.23 and a one year high of $42.29. The stock has a market cap of $927.33 million, a PE ratio of 12.44 and a beta of 0.63. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 EPS for the quarter, missing the consensus estimate of $1.50 by ($0.01). Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The company had revenue of $177.76 million during the quarter, compared to the consensus estimate of $174.96 million. During the same quarter in the previous year, the company earned $1.45 earnings per share. The business's revenue was up 22.7% on a year-over-year basis. Research analysts predict that Collegium Pharmaceutical will post 5.62 earnings per share for the current fiscal year.

Insider Buying and Selling at Collegium Pharmaceutical

In other news, EVP Shirley R. Kuhlmann sold 40,000 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the transaction, the executive vice president now directly owns 154,204 shares of the company's stock, valued at $4,330,048.32. This represents a 20.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Colleen Tupper sold 1,949 shares of the company's stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $30.00, for a total value of $58,470.00. Following the transaction, the chief financial officer now directly owns 177,195 shares in the company, valued at $5,315,850. The trade was a 1.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 81,693 shares of company stock valued at $2,334,994. 2.51% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of institutional investors have recently modified their holdings of COLL. Belpointe Asset Management LLC purchased a new stake in Collegium Pharmaceutical in the 1st quarter valued at $408,000. Fortis Capital Advisors LLC purchased a new stake in Collegium Pharmaceutical in the 1st quarter valued at $408,000. Intech Investment Management LLC raised its position in Collegium Pharmaceutical by 10.1% in the 1st quarter. Intech Investment Management LLC now owns 73,908 shares of the specialty pharmaceutical company's stock valued at $2,206,000 after buying an additional 6,776 shares during the last quarter. Jane Street Group LLC raised its position in Collegium Pharmaceutical by 218.7% in the 1st quarter. Jane Street Group LLC now owns 131,520 shares of the specialty pharmaceutical company's stock valued at $3,926,000 after buying an additional 90,255 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Collegium Pharmaceutical by 7.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,014 shares of the specialty pharmaceutical company's stock valued at $2,120,000 after buying an additional 4,625 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.